A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
Latest Information Update: 11 Aug 2023
At a glance
- Drugs OCV 501 (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 01 Aug 2023 Primary endpoint (Disease-Free Survival) has not been met according to result published in the Cancer Immunology Immunotherapy
- 01 Aug 2023 Results assessing 5-year outcome and biomarkers published in the Cancer Immunology Immunotherapy
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology